236 related articles for article (PubMed ID: 28898054)
1. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
Schniering J; Borgna F; Siwowska K; Benešová M; Cohrs S; Hasler R; van der Meulen NP; Maurer B; Schibli R; Müller C
Mol Pharm; 2018 Nov; 15(11):4995-5004. PubMed ID: 30265552
[TBL] [Abstract][Full Text] [Related]
3. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
4. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
7. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
Molecules; 2020 May; 25(11):. PubMed ID: 32486054
[TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
10. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Deberle LM; Benešová M; Becker AE; Ratz M; Guzik P; Schibli R; Müller C
Bioconjug Chem; 2021 Aug; 32(8):1617-1628. PubMed ID: 34251183
[TBL] [Abstract][Full Text] [Related]
11. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.
Shi J; Liu Z; Jia B; Yu Z; Zhao H; Wang F
Amino Acids; 2010 Jun; 39(1):111-20. PubMed ID: 19941017
[TBL] [Abstract][Full Text] [Related]
13. Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in Balb-C mice.
Pujatti PB; Santos JS; Massicano AV; Mengatti J; De Araújo EB
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):18-24. PubMed ID: 20525454
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
15.
Vats K; Satpati AK; Sharma R; Sarma HD; Satpati D; Dash A
J Pharm Biomed Anal; 2018 Apr; 152():173-178. PubMed ID: 29414010
[TBL] [Abstract][Full Text] [Related]
16. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
17. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
Cho EH; Lim JC; Lee SY; Jung SH
J Pharmacol Sci; 2016 Jul; 131(3):209-14. PubMed ID: 27430985
[TBL] [Abstract][Full Text] [Related]
18. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
19. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
20. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Hens M; Vaidyanathan G; Welsh P; Zalutsky MR
Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
